Specialty Pharma

Thalassaemia and sickle-cell belts across Africa, the Mediterranean and South Asia make iron chelators a durable niche.

High-value and increasingly India's growth engine, from oral targeted therapies to biosimilar monoclonal antibodies.

India is becoming a serious source of affordable enzyme replacement and orphan therapies.

Biosimilars of anti-TNF agents are one of India's strongest high-value export stories.

An under-served corridor with less competition than human generics and a lighter registration burden in most Tier 3 markets.